The Wnt pathway, a notorious driver of cancer growth and drug resistance, has long stumped pharmaceutical researchers, with every broad Wnt inhibition program failing due to severe toxicity. Now, Wynveris, a biotech startup developing first-in-class receptor-selective Wnt inhibitors, has secured $44K in new funding to advance its novel approach.
Wynveris aims to overcome decades of failed attempts by targeting only the specific Wnt receptors a tumor depends on. This precision allows healthy tissue to rely on other receptors, promising to hit cancer hard without the prohibitive side effects that plagued prior treatments and made them too toxic to dose effectively.
